| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.0032 | 1 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.0038 | 1 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |